| | |
Baseline
|
after switch
|
after 3 month
|
after 9 month
|
|---|
| | |
Metab (-)
|
Metab (+)
|
Metab (-)
|
Metab (+)
|
Metab (-)
|
Metab (+)
|
Metab (-)
|
Metab (+)
|
|---|
|
Substance classes
| | | | | | | | | |
|
none
|
%
|
4.9
|
2.7
|
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
ACE-inhibitors
|
%
|
48.2
|
59.3*
|
3.7
|
7.7*
|
3.5
|
7.6*
|
3.5
|
7.0*
|
|
Alpha-blockers
|
%
|
3.2
|
4.1**
|
1.6
|
2.6*
|
1.5
|
2.6*
|
1.5
|
2.6*
|
|
ARBs
|
%
|
4.0
|
4.7
|
98.9
|
99.8*
|
97.6
|
97.7
|
91.9
|
92.0
|
|
Beta-blockers
|
%
|
44.3
|
49.3*
|
25.9
|
34.8*
|
25.3
|
33.7*
|
24.2
|
31.3*
|
|
Diuretics
|
%
|
30.7
|
47.8*
|
7.0
|
14.4*
|
6.5
|
13.6*
|
6.0
|
12.4*
|
|
Calcium antagonists
|
%
|
27.5
|
36.4*
|
13.3
|
22.7*
|
13.4
|
23.0*
|
13.0
|
21.8*
|
|
Irbesartan 75 mg
|
%
|
< 0.1
|
0.0
|
0.3
|
0.2
|
0.3
|
0.1**
|
0.3
|
0.1**
|
|
Irbesartan 150 mg
|
%
|
0.5
|
0.4
|
11.0
|
5.8*
|
8.0
|
3.7*
|
7.5
|
3.2*
|
|
Irbesartan 300 mg
|
%
|
0.1
|
0.2
|
29.8
|
22.0*
|
28.2
|
19.8*
|
25.2
|
17.9*
|
|
Irbesartan 150 mg/12,5 mg HCTZ
|
%
|
< 0.1
|
0.1
|
10.8
|
9.1**
|
8.9
|
6.6*
|
8.4
|
6.1*
|
|
Irbesartan 300 mg/12,5 mg HCTZ
|
%
|
0.1
|
< 0.1
|
46.0
|
62.1*
|
50.4
|
66.0*
|
48.2
|
62.6*
|
- Met (+) – Patients with the metabolic syndrome (doctors' diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: Chi2-test; * p < 0.0001 vs. patients without MS; ** p < 0.01 vs. patients without MS
